Hyundai Bioscience is in talks with an Australian hospital to conduct a global phase 1 clinical trial to test its “pain-free” cancer treatment Polytaxel in humans in the country.

According to a study design unveiled by the Korean drugmaker on Tuesday, Polytaxel will be administered to patients in two or three doses at seven-day intervals. Dosing will be completed eight days after the first dose for the two-dose treatment protocol and 15 days for the three-dose treatment.

Polytaxel was developed with commonly used chemo docetaxel loaded into Hyundai Bioscience’s nano-molecular drug delivery system. This therapy also called NOAEL (No Observed Adverse Effect Level) was designed to deliver ultra-low-toxicity doses and minimize the cancer treatment period to up to eight days.

The polytaxel clinical program has attracted international attention since it was first released at the Global Bio Conference (GBC) hosted by Korean health authorities in 2019.

Hyundai Bioscience said it is in talks with an Australian cancer hospital over its clinical development plan and the phase 1 protocol will be submitted to an Australian human research ethics committee (HREC) as soon as the discussion is over.

Hyundai Bioscience shares were down 3.34 percent at 26,050 won ($19.26) on Wednesday morning.

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]